share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/22 05:22

Moomoo AI 已提取核心信息

At Ensysce Biosciences' Annual Meeting on November 21, 2024, shareholders approved several key proposals, including authorization for a reverse stock split at a ratio between 1:10 and 1:40, to be determined by the Board. Stockholders also approved the issuance of common stock and exercise of warrants to certain investors in compliance with Nasdaq rules.Three Class III Directors were re-elected with terms expiring in 2027: Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin. The appointment of Moss Adams LLP as the company's independent registered public accounting firm for fiscal year 2024 was also ratified by shareholders.The voting results showed strong support for most proposals, with the reverse stock split receiving 4.56 million votes in favor versus 1.99 million against. The fifth proposal regarding meeting adjournment was not submitted to a vote.
At Ensysce Biosciences' Annual Meeting on November 21, 2024, shareholders approved several key proposals, including authorization for a reverse stock split at a ratio between 1:10 and 1:40, to be determined by the Board. Stockholders also approved the issuance of common stock and exercise of warrants to certain investors in compliance with Nasdaq rules.Three Class III Directors were re-elected with terms expiring in 2027: Dr. Lynn Kirkpatrick, Dr. Adam Levin, and Mr. Steve Martin. The appointment of Moss Adams LLP as the company's independent registered public accounting firm for fiscal year 2024 was also ratified by shareholders.The voting results showed strong support for most proposals, with the reverse stock split receiving 4.56 million votes in favor versus 1.99 million against. The fifth proposal regarding meeting adjournment was not submitted to a vote.
在Ensysce Biosciences于2024年11月21日举行的年度会议上,股东批准了几项关键提案,包括授权进行1:10至1:40的反向股票拆分,具体比例由董事会决定。股东还批准了向某些投资者发行普通股和行使Warrants,符合纳斯达克规则。三名三级董事被重新选举,任期至2027年:林·柯克帕特里克博士、亚当·莱文博士和史蒂夫·马丁先生。股东还批准了Moss Adams LLP作为公司2024财政年度的独立注册公共会计事务所。投票结果显示大部分提案得到了强烈支持,其中反向股票拆分获得了456万票赞成,199万票反对。关于会议休会的第五项提案未提交投票。
在Ensysce Biosciences于2024年11月21日举行的年度会议上,股东批准了几项关键提案,包括授权进行1:10至1:40的反向股票拆分,具体比例由董事会决定。股东还批准了向某些投资者发行普通股和行使Warrants,符合纳斯达克规则。三名三级董事被重新选举,任期至2027年:林·柯克帕特里克博士、亚当·莱文博士和史蒂夫·马丁先生。股东还批准了Moss Adams LLP作为公司2024财政年度的独立注册公共会计事务所。投票结果显示大部分提案得到了强烈支持,其中反向股票拆分获得了456万票赞成,199万票反对。关于会议休会的第五项提案未提交投票。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息